Lack of somatic mutations in EGFR tyrosine kinase domain in hepatocellular and nasopharyngeal...

EGFR-targeting monoclonal antibodies in head and neck cancer

I Astsaturov, RB Cohen… - Current cancer drug targets, 2006 - ingentaconnect.com
The epidermal growth factor (EGF) and its receptor were discovered nearly 40 years ago.
Over the past decade interruption of this pathway has been exploited in the treatment of …
被引用次数：71 相关文章 所有 3 个版本

Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer

I Astsaturov, RB Cohen, P Harari - Expert review of anticancer …, 2006 - Taylor & Francis
In this review, key aspects of epidermal growth factor receptor (EGFR) biology and the fruitful
translation of these fundamental findings into recent treatment advances in head and neck …
被引用次数：50 相关文章 所有 6 个版本
[PDF] springer.com

A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma

T Bekaii-Saab, N Williams, C Plass, MV Calero, C Eng - BMC cancer, 2006 - Springer
Background Several studies showed that gain-of-function somatic mutations affecting the
catalytic domain of EGFR in non-small cell lung carcinomas were associated with response …
被引用次数：58 相关文章 所有 24 个版本

EGFR mutation in various tissues

K Nishio, T Arao, T Kato, H Yokote - Cancer chemotherapy and …, 2006 - Springer
Somatic mutations have been demonstrated in various tumors. EGFR mutations were first
demonstrated in adenocarcinoma of the lung, and a large-scale retrospective study has …
被引用次数：5 相关文章 所有 6 个版本

EGFR mutation in various tissues

KNTATKH Yokote - Cancer Chemotherapy and Pharmacology, 2006 - search.proquest.com
Somatic mutations have been demonstrated in various tumors. EGFR mutations were first
demonstrated in adenocarcinoma of the lung, and a large-scale retrospective study has …
相关文章